Researchers, pharmaceutical companies, funders, regulators, and other stakeholders in the scientific fight against Alzheimer???s disease have expressed great interest in the evaluation of putative ???preclinical Alzheimer???s disease treatments,??? interventions that are initiated in cognitively unimpaired persons and intended to postpone, reduce the risk of, or completely prevent progression to t